🇺🇸

US SEC Filing Intelligence

· daily

New Drug Approvals (Original) — March 03, 2026

This one-day snapshot captures 19 original drug approvals from late February 2026, overwhelmingly generic ANDAs (18/19) under standard review with no special designations, signaling routine portfolio expansions for generics-focused sponsors amid competitive pricing pressures. The lone NDA approval for Eton Pharmaceuticals' desmopressin acetate provides the period's only bullish signal, potentially diversifying its portfolio beyond generics norms. Absence of therapeutic areas/indications across most records limits market sizing, emphasizing commoditized generics momentum over innovative breakthroughs.

19 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 03, 2026

Across 34 filings in the USA S&P 500 Consumer Staples intelligence stream (broadly encompassing food, beverages, household, and personal care with some adjacent), key themes include robust revenue growth in reporting companies averaging +29% YoY for Q4 2025 (Rigel +41%, Kontoor +46%, Fuel Tech +37%, Accel +7.5%), margin expansions in high performers (Accel EBITDA +18.9% YoY Q4, Fuel Tech gross +44.6%), and active M&A with premiums (Select Medical 18-25%, Diamond Hill merger approved). Leadership transitions were prevalent and largely positive (Wyndham CFO appt with outlook reaffirm, Massimo CFO, Energy Fuels smooth CEO succession), alongside capital allocation via buybacks (CCEP repurchased 749k shares), debt repayments (Haemonetics $300M full payoff), and equity facilities (PMGC $7.5M prepaid purchase). Forward-looking catalysts cluster in Q2 2026 (mergers, spin-offs), with positive guidance where provided (Rigel $275-290M 2026 rev, Kontoor +9% rev/+15% EPS). Portfolio-level patterns show 6/10 earnings reporters beating YoY revenue trends despite isolated declines (Accel Illinois -2.5% locations), signaling resilient consumer demand but mixed regional/segment performance; sentiment leans positive (14/34 positive/mixed bullish). Risks include softening pricing (SmartStop web rates -13.3% YoY Jan 2026) and M&A execution hurdles, presenting alpha via arb plays and growth outliers.

15 high priority 19 medium 34 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 03, 2026

Across 56 SEC filings from the USA S&P 500 Industrials stream (broadly including adjacent sectors like pharma/biotech due to filing mix), overarching themes include robust revenue growth in 18/56 companies averaging +22% YoY (e.g., Limbach +24.7%, Rigel +60% FY product sales), offset by margin compression in 9/56 (avg -150 bps, e.g., Limbach gross margin -160 bps) and mixed EBITDA trends (up in 12, down in 8). Capital allocation leans shareholder-friendly with buybacks (Limbach $50M program) and debt refinancings lowering costs (Adtalem -50 bps margins, Howmet $1.2B notes for acquisition). Forward-looking catalysts cluster in H1-H2 2026: 7 guidances raised/issued (e.g., Limbach $730-760M rev), 5 trial readouts (Amylyx Q3, Karyopharm mid-2026), Honeywell Aerospace spin-off progress, and M&A closes (Howmet CAM by 2026). Industrials-specific patterns show M&A/outperformance (Howmet $1.8B deal, Limbach ODR +40.6%), while pharma dominates positive pipeline (MIRA Phase 1 success, Rigel R289 H2 data). Portfolio implications: overweight growth industrials/services amid resilient demand, monitor pharma trial risks; no broad insider selling detected, but repurchases signal conviction in 3 firms.

21 high priority 35 medium 56 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 03, 2026

Across the two filings in the USA S&P 500 Energy intelligence stream, key themes emerge around strategic growth via M&A and strong executive performance incentives, though filings span adjacent high-growth areas like security tech and biotech with energy-adjacent applications. Knightscope's acquisition of Event Risk LLC highlights accretive expansion into managed security services with double-digit growth assets, while Stoke Therapeutics rewards CEO Ian F. Smith with a $697,125 bonus for 150% goal achievement in 2025. No period-over-period financial trends (YoY/QoQ revenue, margins) or insider trading activity were detailed, limiting quantitative portfolio comparisons, but both exhibit positive sentiment (Knightscope 9/10 materiality, Stoke 6/10). Forward-looking catalysts include Knightscope's GSX conference presentation later in 2026 and plans for additional acquisitions, signaling portfolio-level M&A momentum. Capital allocation appears shareholder-friendly via growth investments, with no dividend/buyback data disclosed. Overall, bullish signals dominate, but lack of detailed metrics prevents robust sector margin/growth trend synthesis.

2 high priority 2 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 03, 2026

Across 248 SEC filings from S&P 500 Financials and adjacent sectors (despite diverse inclusions like healthcare, mining, and tech), dominant themes include robust M&A activity (e.g., 12+ deals like Select Medical's $3.9B takeover at 25% premium, RAPT's $58/share tender), mixed Q4/FY2025 earnings with revenue growth averaging +10% YoY in reporting firms (e.g., Accel +8.1%, Evolus +12%) but frequent margin compression (-100 to -200 bps in 15+ cos like STAAR, THOR), and aggressive capital returns via buybacks/dividends (e.g., Pinterest $2B repurchase, MarketWise $0.45 special dividend). Leadership transitions signal stability (20+ CEO/CFO changes, mostly positive like Wyndham's CFO appt), while debt refinancings/issuances (25+ events, e.g., RGA $400M notes, Leidos $1.4B) bolster liquidity amid high interest environments. Forward guidance shows cautious optimism (e.g., Limbach $730-760M rev +13% mid, EVgo $410-470M +20%), but risks from delistings (Trinseo), restatements (Century Aluminum), and covenant waivers persist. Portfolio-level trends: 40% filings positive sentiment, 35% mixed, with YoY revenue up in 60% of earners but EBITDA mixed; insider patterns limited but sales rare, buys absent; catalysts cluster mid-2026 (closings, earnings). Implications: overweight M&A targets/premiums, monitor margin squeezes in cyclicals, favor cap alloc leaders for returns.

96 high priority 152 medium 248 total filings
· daily

US Material Events SEC 8-K Filings — March 03, 2026

Across 73 SEC filings dated March 3, 2026, dominant themes include a surge in M&A activity (10+ deals like Flowco's $200M Valiant acquisition, Esperion's $75M+ Enbumyst buy, Knightscope's Event Risk integration), extensive leadership transitions (25+ cases, mostly orderly retirements/appointments boosting expertise in healthcare/tech/energy), and robust capital markets engagement with $5B+ in debt issuances/refinancings (e.g., Leidos $1.4B notes, Vertiv $2.1B notes achieving IG status), share repurchases ($2B Pinterest ASR, $100M Trex), and equity facilities. Period-over-period trends show strong revenue growth in available data (Evolus FY2025 +12% YoY to $297M, Black Rock FY2025 +24.5% YoY to $200M, Byrna 84% CAGR to $118M), though mixed operating margins (Evolus non-GAAP loss widened, Black Rock op income -85% YoY). Positive sentiment prevails (45/73 filings), signaling sector resilience in healthcare (15 filings), energy (8), and consumer (6), with forward catalysts like Q2 2026 deal closes and H1 earnings. Portfolio-level patterns highlight undervalued buybacks amid M&A premiums (e.g., Select Medical 25% premium), but liquidity strains in biotechs (Karyopharm going concern). Implications: Bullish for M&A arbitrage and growth stocks, cautious on small-cap distress.

73 high priority 73 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 03, 2026

Across 12 SEC 8-K filings in the USA S&P 500 Technology stream (though spanning utilities, biotech, finance, and consumer alongside core tech like CrowdStrike and IBM), dominant themes include capital raising via at-the-market (ATM) offerings (TXNM Energy $125M, Tharimmune/Canton $300M), mixed financial results with revenue growth in CrowdStrike (+23% YoY Q4 FY26 to $1.31B, ARR +24% to $5.25B) offset by NAV declines in Oxford Square Capital (-13% QoQ to $1.69/share) and persistent net losses in Immunome (-$212M FY25, improved 27% YoY), and forward-looking catalysts like partnerships (Adial $60M potential) and guidance raises (CrowdStrike FY27 ARR $6.47B-$6.52B). Period-over-period trends show selective strength in subscription margins (CrowdStrike +200bps YoY GAAP Q4) and cash runway extensions (Immunome to 2028 via $432M net raise), but dilution risks from ATMs and failed quorums (Adial). Exec changes signal transitions (Smucker COO separation, Community West COO retirement), while capital allocation leans toward distributions (Oxford monthly $0.035/share) and buybacks (CrowdStrike $51M). Overall neutral-to-mixed sentiment (8/10 filings neutral/mixed) implies portfolio caution in tech, favoring CrowdStrike outperformance amid sector growth but watching biotech/fintech volatility for alpha.

6 high priority 6 medium 12 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 03, 2026

Across 10 SEC 8-K filings from NASDAQ-100 constituents on March 3, 2026, dominant themes include capital raising via at-the-market (ATM) offerings by TXNM Energy ($125M) and Canton Strategic Holdings/Tharimmune ($300M), signaling liquidity bolstering amid neutral sentiment; executive transitions at Intel (Chair retirement), J.M. Smucker (COO separation), and Community West Bancshares (COO retirement); and biotech advancements with Immunome's 27% YoY net loss improvement to $212.4M, cash runway to 2028, and Phase 3 success (84% risk reduction, HR=0.16), alongside Adial's mixed Europe partnership potential (~$60M value). Period-over-period trends are limited but highlight Immunome's R&D expenses up 37% YoY to $177.3M and collaboration revenue down 23% to $6.9M, contrasting sharply improved loss per share ($(2.43) vs. $(5.00)). No insider trading activity reported across filings, but TXNM's 2026 incentive plans tie bonuses to EPS thresholds (up to 230% salary) and LTIP to earnings growth/FFO metrics through 2028, aligning management. Portfolio-level patterns show dilution risks from ATMs (total ~$425M potential), offset by Immunome's strong pipeline catalysts and Adial's commercialization pathway, with neutral-to-mixed sentiment (6/10 neutral) implying stable but non-explosive near-term implications; investors should prioritize biotech catalysts over governance noise.

6 high priority 4 medium 10 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 03, 2026

Across 79 SEC filings from DJ30-related and associated US blue-chips on March 3, 2026, dominant themes include robust M&A activity (e.g., Select Medical $3.9B takeover at 18-25% premium, Flowco $200M Valiant acquisition), mixed Q4/FY2025 earnings with average revenue growth of ~20% YoY in reporting firms (e.g., EVgo +75% Q4, Limbach +24.7% FY) offset by widespread margin compression averaging -150bps (e.g., Mayville EBITDA margin 7.6% to 4.7%, Limbach gross 27.8% to 26.2%). Capital allocation leans shareholder-friendly with buybacks (Limbach $50M, Civeo 10% authorization, Kontoor $25M) and dividends (Versant $0.375/share), alongside debt refinancings improving terms (Vertiv investment-grade upgrade, Adtalem lower margins). Forward guidance for 2026 shows cautious optimism with revenue growth projections of 5-15% in most (e.g., CrowdStrike ARR to $6.47-6.52B +24% implied), but flat/declining EBITDA in others (EVgo -$20M to $20M). Insider activity is minimal but neutral (e.g., Innventure tax withholdings), with no major sells signaling conviction. Portfolio-level trends flag healthcare/tech outperformance vs. cyclical softness in manufacturing/energy, with 12/79 filings highlighting spin-offs/divestitures (Honeywell Aerospace, Ziff Davis $1.2B Connectivity sale) as deleveraging catalysts. Overall, actionable alpha lies in M&A premiums and guidance beats amid tariff/inflation risks.

31 high priority 48 medium 79 total filings
· daily

US SEC Filings Daily Market Digest — March 03, 2026

Across 385 SEC filings for March 3, 2026, healthcare and biotech dominate with 45+ earnings/milestones showing mixed YoY revenue growth averaging +25% (e.g., Rigel +41%, Strata Critical +83.5%) but persistent net losses narrowing in 60% of cases; retail reports mixed comp sales (-2.5% Target to +9% Ross Stores) with margin expansion in resilient names (Best Buy +360bps to 5.2%). M&A activity surges with 15+ deals (e.g., Select Medical $16.50/share premium, RAPT $58/share acquisition), while financings/debt issuances exceed 50 (e.g., TXNM $125M ATM, Reinsurance Group $400M notes). Capital returns strong: 20+ dividends/buybacks (Best Buy div +1%, Pinterest $2B repurchases). Portfolio trends: margins compress in 7/15 industrials (-150bps avg) but expand in consumer/health (+200bps avg); insider conviction low volume but positive (e.g., no major sells). Neutral ETF/prospectus filings (120+) signal routine compliance. Forward catalysts cluster mid-2026 (Phase 3 data, mergers). Overall, bullish on healthcare catalysts, cautious retail/debt-heavy names amid going concern flags (3 cases).

207 high priority 178 medium 385 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 03, 2026

Across 50 filings from the S&P 500 Consumer Discretionary stream (broadly including retail, autos, and adjacent), sentiment is mixed-positive with 18 positive, 12 mixed, 10 neutral, and few negative, driven by robust M&A (e.g., Flowco $200M, Cal-Maine $130M, Ziff Davis $1.2B divestiture) and capital returns (Ross Stores $2.55B buyback +21%, MarketWise $0.45 total dividend), offsetting earnings pressures. Period-over-period trends show retail sales growth averaging +7% YoY in outperformers like Ross (+12%) and AutoZone (+8%) but declines in Target (-1.5%) and B&G Foods (-2.2%), with margin compression widespread (-137bps AutoZone, -260bps L.B. Foster). Capital allocation leans shareholder-friendly (dividend hikes, buybacks, debt refinancings lowering costs like HA Sustainable 8% to 7.125%), while forward guidance is cautious (Target ~2% sales growth, Ross 3-4% comps). Insider conviction absent in most but supported by 10b5-1 plans (Smart Sand) and board expansions. Key implications: tactical buys in strong retail comps amid M&A wave, watch margin trends and Q1 catalysts for portfolio rotation.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 03, 2026

Across 17 SEC filings from the USA S&P 500 Healthcare stream (including biotech, pharma, providers, and tangential sectors), key themes include positive regulatory milestones and M&A approvals in biotech (e.g., FDA Priority Review, merger votes), mixed financial results with revenue growth in some (Prime Medicine +55% YoY) offset by widening losses (CalciMedica net loss +116% YoY), aggressive capital returns via buybacks (Roivant $1B new program, Civeo new 10% authorization), and leadership transitions (Cigna CEO retirement, Protagenic new President). Period-over-period trends show 3/5 reporting companies with YoY revenue growth (avg +29%) but 4/5 with wider net losses (avg +42%), highlighting R&D intensity in biotech; Australian operations boosted Civeo Q4 EBITDA +90% YoY. Critical developments like Roivant's $2.25B Moderna settlement and Ventyx's 96% merger approval signal liquidity boosts and strategic exits, while trial setbacks (CalciMedica) flag risks. Portfolio-level patterns reveal biotech conviction via capital allocation (buybacks up) amid cash runways into 2027, positioning sector for catalysts but vulnerable to clinical risks.

4 high priority 13 medium 17 total filings
· daily

Global High-Priority Regulatory Events — March 03, 2026

Across 236 filings dominated by US SEC 8-Ks and routine fund prospectus certifications (497J/K ~60%), critical themes include robust M&A/takeover activity (e.g., Select Medical $3.9B EV at 25% premium, Flowco $200M acquisition, Knightscope bolt-on), leadership transitions (positive in Byrna, Wyndham; neutral elsewhere), and capital raises/refinancings (TXNM $125M ATM, Leidos $1.4B notes for ENTRUST). Period trends show mixed revenue growth: Evolus Q4 +14% YoY/$90.3M, Black Rock Coffee Q4 +25.3% YoY/$53.6M but FY net loss -130% to $16.5M; margins compressed in some (RYAM Q4 EBITDA -$5M YoY). Indian firms faced clustered SEBI fines for board non-compliance (e.g., Bharat Heavy, Hindustan Copper ~₹5-10L each, 10+ cases), signaling governance risks. Forward guidance stable/positive (Evolus 10-13% rev growth 2026, Wyndham reaffirmed), with capital returns via dividends (Mangalore ₹4/share, 40%, record Mar 11), buybacks (Pinterest $2B H1 2026), and debt optimization (Reinsurance $396M net, Vertiv IG upgrade). Portfolio-level: Healthcare M&A bullish, energy financings neutral, funds neutral (low materiality). Implications: Tactical opportunities in take-private premiums, monitor Indian governance for shorts, favor US growth names amid stable guidance.

236 high priority 236 total filings
· daily

US Executive Officer Management Changes SEC — March 03, 2026

Across 32 filings on US executive and director changes dated March 3, 2026, dominant themes include orderly planned retirements and successions (e.g., Cigna, Energy Fuels, Nucor), experienced appointments (e.g., Wyndham CFO, Massimo CFO, Protagenic President), and compensatory updates (severance plans, bonuses, LTIPs in 12 firms), with 14 positive, 12 neutral, and 4 mixed sentiments signaling management stability amid sector diversity from banking to biotech and energy. Period-over-period trends highlight outliers like Black Rock Coffee's Q4 2025 revenue +25.3% YoY and SSS +9.3%, Byrna's 84% CAGR revenue growth since 2019, and CigNA's revenue expansion from $18B to $275B (+1428% over 17 years) with +750% TSR, contrasting Prairie Operating's leadership vacuum. No widespread insider selling noted, but capital allocation via debt repayment (Black Rock reduced term loan by $30.1M) and equity grants (e.g., Target Hospitality PSUs up to 200% vesting) supports shareholder alignment. Forward-looking reaffirmations (Wyndham, Cigna 2026 outlooks) and guidance (Black Rock FY2026 revenue $255-257M, EBITDA $33.5-34.5M) indicate confidence, though interim CEOs (Prairie) flag transition risks. Portfolio implications favor long-term holders in growth firms with smooth handovers, monitoring oil/gas for leadership gaps.

32 high priority 32 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 03, 2026

Across 44 filings in the USA Corporate Distress & Bankruptcy stream, overarching themes include proactive debt refinancing and covenant relief (e.g., 10+ amendments/extensions providing liquidity runway), healthcare/biotech M&A and settlements amid distress signals (12 filings), and equity raises/buybacks signaling confidence in select names despite Nasdaq deficiencies and delistings (4 cases). Period-over-period trends are sparse but reveal mixed revenue performance: Evolus +14% YoY Q4/+12% FY 2025 revenue with GAAP profitability in Q4, contrasting RYAM's -1% YoY Q4 sales and worsening $21M loss; no broad margin compression but operational cash strains in 3 names (e.g., RYAM -$88M Adj FCF). Critical developments: Trinseo NYSE delisting (immediate suspension), Karyopharm going concern doubt tied to $25M equity raise by June 2026, and Arbutus/Genevant $2.25B Moderna settlement (upfront July 2026). Portfolio-level patterns show 15/44 positive sentiments (refinancings, acquisitions), 8 negative (delistings, deficiencies), with healthcare (18/44) dominant for distress signals but also opportunities; implications favor monitoring liquidity extensions as buyout catalysts while avoiding delisting risks.

44 high priority 44 total filings
· daily

US SEC Trading Suspension Halt Orders — March 03, 2026

Three US-listed companies—Trinseo PLC (NYSE), PDS Biotechnology Corp (Nasdaq), and CVR Partners LP (NYSE)—face critical listing compliance deficiencies announced in early March 2026, signaling heightened delisting risks amid weak market caps, share prices, and governance structures. Trinseo faces immediate trading suspension and delisting due to average market cap below $15M over 30 days, following prior December 2025 warnings for $50M equity thresholds and sub-$1 share price. PDSB received a Nasdaq notice for 30 consecutive days below $1.00 bid price, with 180 days to comply via potential reverse split. CVR Partners disclosed audit committee non-compliance after director death, reducing independents below NYSE Section 303A.07(a) requirements. No period-over-period financial trends available, but persistent low market caps and prices indicate deteriorating shareholder value and liquidity. Portfolio-level pattern: Small-cap distress with immediate (Trinseo) to medium-term (PDSB, CVR) catalysts for suspensions/delistings, implying sector-agnostic compliance failures in chemicals, biotech, and fertilizers.

3 high priority 3 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 03, 2026

Across 31 SEC filings on USA Board Room Changes from March 3, 2026, a dominant theme is orderly leadership transitions with 12 CEO/President/CFO appointments or promotions highlighting experienced hires (e.g., Byrna, Wyndham, Cigna, Massimo), 10 retirements/resignations without disagreements (e.g., Nucor, PCA, Northpointe), and 5 interim roles signaling searches (Prairie Operating). Positive sentiment prevails in 14 filings (45%), driven by growth legacies like Cigna's 750% TSR and Byrna's 84% CAGR revenue growth from $0.25M to $118M, while mixed/neutral tones in 15 reflect change-of-control (Slam Corp) or vague details (ACRG). Period trends show outliers like Black Rock Coffee's Q4 2025 revenue +25.3% YoY and SSS +9.3%, but FY net loss widened 130.1%; Wyndham boasts 20 straight quarters of net room growth. No broad insider selling/buying patterns, but capital allocation via equity grants (e.g., Protagenic 1% dilution, Target Hospitality PSUs) and severance enhancements (Group 1, Simmons) indicate retention focus amid no major guidance cuts—Wyndham/Cigna reaffirmed 2026 outlooks. Portfolio implications favor monitoring healthcare/energy for succession stability boosting TSR, while small-caps risk interim leadership gaps.

31 high priority 31 total filings
· daily

US Merger & Acquisition SEC Filings — March 03, 2026

The 7 filings reveal a vibrant USA M&A and takeover landscape dominated by SPAC activity (4/7 filings), with two fresh IPOs raising $225M combined ($100M APEX, $125M Clearthink), one extension to March 2027 with near-zero redemptions (Piermont), and operational funding via $1.5M note (Valuence), signaling investor appetite for blank-check vehicles amid no explicit YoY/QoQ financial trends but strong forward momentum. Strategic tuck-ins shine with Knightscope's acquisition of EBITDA-positive Event Risk LLC (double-digit growth, Fortune 1000 clients), poised for revenue density via robotics integration, while Duke Energy locks in $2.8B initial minority stake from Brookfield (phased to $6B total by 2028, 19.7% ownership). RAPT Therapeutics flags a bearish privatization/delisting with drastic share reduction to 1,000 and control shifts. Positive sentiment prevails (5/7 filings), with materiality at 9/10 for most, highlighting M&A as a key growth lever; no insider trades noted but capital inflows underscore conviction. Portfolio implication: overweight SPACs and acquisitive tech/energy for near-term catalysts like GSX conference and phased closings.

7 high priority 7 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 03, 2026

Overnight SEC filings (626 total) dominated by routine 497K/J fund prospectuses (95%+ volume) showing pervasive mixed/neutral sentiment with most active funds underperforming S&P 500 benchmarks long-term (e.g., 10/12 Hennessy funds trailed 14.82% 10Y return avg by 200-500bps) amid high turnover (avg 80%) and sector concentrations, signaling caution on active mid/small-cap strategies vs passive indices. Operational companies highlighted positive milestones like Aptera's first vehicle production (+8/10 materiality) and Byrna's revenue 84% CAGR under retiring CEO, but mixed earnings (Limbach rev +25% YoY yet GCR -7%, AutoZone SSS +3.3% but margins -137bps). Biotech M&A active (Rallybio/Candid $750M rev merger diluting legacy holders to 3.65%; Freenome de-SPAC H1 2026) with positive pipeline catalysts; SPAC/control changes (Slam Corp full equity shift to crypto/DeFi experts). Capital allocation bullish in repurchases (NRG $300M, BrightSpring $60M potential) but insider selling patterns in funds/mixed signals. Portfolio trend: margin compression avg -100bps in 6/10 detailed earnings despite rev growth +15% avg YoY; forward catalysts cluster Q2 2026 (FDA nods, mergers). Implications: favor passive ETFs/index hugging, monitor biotech/SPAC dilutions, buy dips in infra/energy acquirers.

568 high priority 58 medium 626 total filings
· daily

Significant Contract Modifications ($10M+) — March 02, 2026

A single $253,723 firm-fixed-price contract to Lockheed Martin from NASA Goddard underscores neutral, low-materiality activity in space R&D for Mars end-to-end service architectures. The 3-month performance period (Mar-May 2026) with $0 outlays limits near-term revenue visibility and portfolio impact. This isolated award aligns with NASA's Mars focus but signals no broader trends warranting immediate position changes.

1 total filings